Drug Trial Radar · NCT03213002
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Mar 25, 2018
Primary completion
Jun 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Northwell HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.
Conditions
- Glioblastoma Multiforme (GBM)
- Glioblastoma
- Glioma of Brain
- Glioblastoma, Adult
- Brain Tumor
- Brain Tumor, Primary
- Brain Tumor Adult
- Cancer
- Brain Cancer
Interventions
CapecitabineDrug
Capecitabine at 1500 mg/m2
TemozolomideDrug
Temozolomide at 150 mg/m2 - 200 mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: 6 months
- Overall Survival (OS)Time frame: 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lenox Hill Brain Tumor Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.